Risk Factors Associated with Disease-specific Mortality in Papillary Thyroid Cancer Patients with Distant Metastases

Overview

Journal Endocrine

Specialty Endocrinology

Date 2021 Oct 19

PMID 34665427

Citations 10

Authors

Kamilla Schmitz Nunes

Leandro Luongo Matos

Beatriz Godoi Cavalheiro

Felipe Ferraz Magnabosco

Marcos Roberto Tavares

Marco Aurelio Kulcsar

Ana Oliveira Hoff

Luiz Paulo Kowalski

Ana Kober Leite

Affiliations

Soon will be listed here.

Abstract

Purpose: Papillary thyroid carcinoma (PTC) is among the most curable cancer types. Even though uncommon, some patients present distant metastatic disease at diagnosis or during the follow-up and most of them have long-term survival. However, there continues to be controversies regarding what clinicopathological features are associated with mortality in these patients. This paper evaluates the factors related to poor disease-specific survival (DSS) in patients with metastatic PTC.

Methods: A retrospective cohort study included PTC patients with distant metastasis from a tertiary public oncological center. Clinicopathological features, treatment modalities, and outcome were reviewed.

Results: Between 1986 and 2014, 108 patients were diagnosed with metastatic PTC. In the multivariate analysis male sex (HR = 2.65; 95%CI: 1.08-6.53; P = 0.033), radioiodine refractory disease (HR = 9.50; 95%CI: 1.23-73.38; P = 0.031) and metastasis at multiple sites (HR = 5.91; 95%CI: 1.80-19.32; P = 0.003) were independent risk factors for death in patients with metastatic PTC.

Conclusion: Male patients with metastatic PTC, with radioiodine refractory disease and metastasis at multiple sites have a high risk of death.

Citing Articles

Evaluation of epithelial-to-mesenchymal transition and Ki-67 index in aggressive papillary thyroid cancer.

Camilo L, Vianna P, Alves V, Cavalheiro B, Rossetti C, Kowalski L Braz J Otorhinolaryngol. 2024; 91(1):101510.

PMID: 39388828 PMC: 11497440. DOI: 10.1016/j.bjorl.2024.101510.

Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer.

Mu Z, Zhang X, Liang D, Fang J, Chen G, Guo W Chin J Cancer Res. 2024; 36(1):25-35.

PMID: 38455372 PMC: 10915639. DOI: 10.21147/j.issn.1000-9604.2024.01.03.

Diagnosing postoperative lymph node metastasis in thyroid cancer with multimodal radiomics and clinical features.

Fan X, Zhang H, Wang Z, Zhang X, Qin S, Zhang J Digit Health. 2024; 10:20552076241233244.

PMID: 38384366 PMC: 10880541. DOI: 10.1177/20552076241233244.

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.

Mu Z, Zhang X, Sun D, Sun Y, Shi C, Ju G J Clin Endocrinol Metab. 2023; 109(5):1231-1240.

PMID: 38060243 PMC: 11031230. DOI: 10.1210/clinem/dgad697.

Circular RNA EIF3I promotes papillary thyroid cancer progression by interacting with AUF1 to increase Cyclin D1 production.

Yao X, Liu H, Wang Z, Lu F, Chen W, Feng Q Oncogene. 2023; 42(43):3206-3218.

PMID: 37697064 DOI: 10.1038/s41388-023-02830-3.

References

Kitahara C, Sosa J . The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016; 12(11):646-653. PMC: 10311569. DOI: 10.1038/nrendo.2016.110. View

Davies L, Welch H . Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295(18):2164-7. DOI: 10.1001/jama.295.18.2164. View

Carling T, Udelsman R . Thyroid cancer. Annu Rev Med. 2013; 65:125-37. DOI: 10.1146/annurev-med-061512-105739. View

Cavalheiro B, Leite A, Matos L, Palermo Miazaki A, Marcel Ientile J, Kulcsar M . Malignancy Rates in Thyroid Nodules Classified as Bethesda Categories III and IV: Retrospective Data from a Tertiary Center. Int J Endocrinol Metab. 2018; 16(1):e12871. PMC: 5903393. DOI: 10.5812/ijem.12871. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

Lim H, Devesa S, Sosa J, Check D, Kitahara C . Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013. JAMA. 2017; 317(13):1338-1348. PMC: 8216772. DOI: 10.1001/jama.2017.2719. View

Ito Y, Miyauchi A . Active surveillance of low-risk papillary thyroid microcarcinomas. Gland Surg. 2020; 9(5):1663-1673. PMC: 7667125. DOI: 10.21037/gs-2019-catp-03. View

van Velsen E, Stegenga M, van Kemenade F, Kam B, van Ginhoven T, Visser W . Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. Thyroid. 2018; 28(8):976-981. DOI: 10.1089/thy.2018.0066. View

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

10.

Benbassat C, Mechlis-Frish S, Hirsch D . Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006; 30(6):1088-95. DOI: 10.1007/s00268-005-0472-4. View

11.

Ronga G, Filesi M, Montesano T, Melacrinis F, Di Nicola A, Ventroni G . Death from differentiated thyroid carcinoma: retrospective study of a 40-year investigation. Cancer Biother Radiopharm. 2002; 17(5):507-14. DOI: 10.1089/108497802760804736. View

12.

Siironen P, Louhimo J, Nordling S, Ristimaki A, Maenpaa H, Haapiainen R . Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol. 2005; 26(2):57-64. DOI: 10.1159/000085586. View

13.

Ito Y, Kihara M, Takamura Y, Kobayashi K, Miya A, Hirokawa M . Prognosis and prognostic factors of papillary thyroid carcinoma in patients under 20 years. Endocr J. 2012; 59(7):539-45. DOI: 10.1507/endocrj.ej12-0086. View

14.

Lang B, Lo C, Chan W, Lam K, Wan K . Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. 2006; 14(2):730-8. DOI: 10.1245/s10434-006-9207-5. View

15.

Shaha A, Shah J, Loree T . Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg. 1997; 174(5):474-6. DOI: 10.1016/s0002-9610(97)00158-x. View

16.

Cady B, Rossi R . An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988; 104(6):947-53. View

17.

Hay I, Grant C, Taylor W, McConahey W . Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987; 102(6):1088-95. View

18.

Hay I, Bergstralh E, Goellner J, Ebersold J, Grant C . Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993; 114(6):1050-7; discussion 1057-8. View

19.

Sugitani I, Fujimoto Y, Yamamoto N . Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery. 2007; 143(1):35-42. DOI: 10.1016/j.surg.2007.06.011. View

20.

Dinneen S, Valimaki M, Bergstralh E, Goellner J, Gorman C, Hay I . Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995; 80(7):2041-5. DOI: 10.1210/jcem.80.7.7608252. View